Use of the tumor necrosis factor-blockers for Crohn's disease

Table 37 Adverse effects for infliximab and adalimumab¹

	IFX	ADA
All AEs	-	-
Serious AEs	-6.6	-4.72
Nausea	+7.93	+2.4
Pharyngitis	+16.1	+3.72
Injection site infection	-	+3.82
Injection site reaction	-	+10.52
Arthralgias	-	+4.32
Urinary tract infections	-	+3.52

¹The rates are shown as the percentage differences in the rates of AEs in tumor necrosis factor-α blocker minus placebo groups. AEs are shown, with the increased (+) or decreased (-) difference from placebo. Note that the duration of follow-up observation varied between study, and has not been standardized here (e.g., per 100 treatment years);

²The statistically significant or trends: (1) Note that the rates of all AEs as well as serious AEs were lower than in the placebo groups; and (2) Serious AEs include lymphoma and other cancers;

³Significant difference. IFX: Infliximab; ADA: Adalimumab; AEs: Adverse effects.